An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
Since the beginning of the COVID-19 pandemic, large in silico screening studies and
numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV …
numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV …
[HTML][HTML] Development of remdesivir as a dry powder for inhalation by thin film freezing
S Sahakijpijarn, C Moon, JJ Koleng, DJ Christensen… - Pharmaceutics, 2020 - mdpi.com
Remdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for
emergency use. To maximize delivery to the lungs, we formulated remdesivir as a dry …
emergency use. To maximize delivery to the lungs, we formulated remdesivir as a dry …
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19
V Backer, U Sjöbring, J Sonne, A Weiss… - The Lancet Regional …, 2021 - thelancet.com
Background Coronavirus disease 19 (COVID-19) is spreading globally and treatment
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B. 1.1. 7), Beta (B. 1.351) …
SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the
great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 …
great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 …
[HTML][HTML] In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters
Remdesivir dry powder for inhalation was previously developed using thin film freezing
(TFF). A single-dose 24-h pharmacokinetic study in hamsters demonstrated that pulmonary …
(TFF). A single-dose 24-h pharmacokinetic study in hamsters demonstrated that pulmonary …
A Niclosamide-releasing hot-melt extruded catheter prevents Staphylococcus aureus experimental biomaterial-associated infection
Biomaterial-associated infections are a major healthcare challenge as they are responsible
for high disease burden in critically ill patients. In this study, we have developed drug-eluting …
for high disease burden in critically ill patients. In this study, we have developed drug-eluting …
Emerging Process Modeling Capabilities for Dry Powder Operations for Inhaled Formulations
Dry powder inhaler (DPI) products are commonly formulated as a mixture of micronized drug
particles and large carrier particles, with or without additional fine particle excipients …
particles and large carrier particles, with or without additional fine particle excipients …
Novel inhalable nano-based/microparticles for enhanced sustained pulmonary delivery of remdesivir-a patient malleable treatment for coronaviruses infection: in vitro …
Remdesivir (RDV) is an antiviral used in potential treatment of SARS-COV-2 infection during
the COVID-19 pandemic worldwide. However, it is still limited to IV administration for …
the COVID-19 pandemic worldwide. However, it is still limited to IV administration for …
[PDF][PDF] Lung Delivery Systems to Optimize Pharmacotherapy of COVID-19: A Concise Review
MG Alrashedi, AG Alrashedi, AS Ali… - J. Pharm. Res. Int, 2021 - researchgate.net
Background: COVID-19 is an ongoing viral pandemic caused by the SARS-COV-2 virus.
Several drugs were repurposed for its management; however, most of these drugs were not …
Several drugs were repurposed for its management; however, most of these drugs were not …